Cardiovascular disease (CVD) is the leading cause of death worldwide: no other cause causes as many deaths each year as CVD.

An estimated 17,9 million people died from CVD in 2016, accounting for 31% of all deaths worldwide. 85% of these deaths were due to heart attack and stroke. Most cardiovascular diseases can be prevented by addressing risk factors such as tobacco use, unhealthy diet and obesity, physical inactivity and harmful use of alcohol through population-wide strategies [1].

In Uzbekistan, the risk of premature death (among the population aged 30-69 years) from the four major NCD groups is approximately 31%; CVD is the leading cause of death. A quarter of adults aged 18-64 and almost a third of adults aged 40-64 are at high risk of having a heart attack or stroke within the next 10 years. Men are particularly at risk for cardiovascular risk given their tobacco use and the harmful use of alcohol. In general, men tend to underuse health services; blood pressure in this population is also under-controlled [2].

As tobacco use, unhealthy diet, obesity and physical inactivity

https://www.who.int/ru/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

Sadyrova M., Aniezova D. , , Farrington J. _ , Choi E.

http://www.euro.who.int/en/health-systems-response-to-NCDs

Makhamadkhojaeva M.A. , Doniev I. Risk factors for cardiovascular diseases // SCIENTIFIC PROGRESS. - 2021. - p.1902-1906.

https://cyberleninka.ru/article/n/faktory-riska-serdechno-sosudistyh-zabolevaniy ?

https://www.who.int/ru/news-room/fact-sheets/detail/hypertension

Oganov R.G. The concept of risk factors as the basis for the prevention of

cardiovascular diseases. Doctor 2001; No7: 3-6.

Prevention, diagnosis and treatment of novel coronavirus disease (COVID-19). Temporary guidelines. Ministry of Health of Russia (March 3, 2020).

WHO : Coronavirus disease ( COVID -19) dashboard

Coronavirus disease 2019 (COVID-19) - Symptoms, diagnosis and treatment. BMJ Best Practices (December 21, 2020).

https://coronavirus-control.ru/coronavirus-uzbekistan/

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process ( English). World Health Organization (19-08-2021).

COVID-19 Vaccine Effectiveness Research | CDC (English). www.cdc.gov (August 11 , 2021).

Mark W. Tenforde . Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 ( English ) // MMWR. Morbidity and Mortality Weekly Report. — 2021.

https://ourworldindata.org/covid-vaccinations

Korostovtseva L.S. , Rotar O.P. , Konradi A.O. COVID -19: what are the risks of patients with arterial hypertension? // Scopus , BAK - 2020

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Intern J Infectious Dis. 2020; doi:10.1016/ j.ijid.2020.03.017

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. dx.doi.org/10.1016/S0140- 6736(20)30566-3

Lian J, Jin X, Hao S, Cai H, Zhang S, Zheng L et al. Analysis of epidemiological and clinical features in older patients with corona virus disease 2019 (COVID-19) out of Wuhan. Clin Infect Dis. 2020; pii : ciaa242. doi:10.1093/ cid /ciaa242

Wang L, He W, Yu X, Hu D, Bao M, Liu H et al. Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infection. 2020. doi:10.1016/j. jinf.2020.03.019

Shlyakhto E. V. , Konradi A. O., Arutyunov G. P., Arutyunov A. G., Bautin A. E.,

Boytsov S.A., Villevalde S.V., et al. Guidelines for the diagnosis and treatment of diseases of the circulatory system (CVD) in the context of the COVID-19 pandemic.// Russian Journal of Cardiology 2020; 25(3): 129-48. doi : 10.15829/1560-4071-2020-3-3801

20. Sergienko I.V., Rezinkina P.K. Novel coronavirus infection COVID-19 and cardiovascular diseases. Peculiarities therapy . Atherosclerosis and dyslipidemia . 2021; No2: 5-23. doi : 10.34687/2219-8202.JAD.2021.02.0001

21. European Center for Disease Prevention and Control. risk groups for severe influenza. 2020. Available at: https:// www.ecdc.europa.eu/en/ seasonal-influenza/prevention-and- control/vaccines/risk-groups (accessed June 27, 2020).

22. A.H.A.; ACC; National Heart, Lung, and Blood Institute, Smith SC, Allen J., Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L., Jones D., Krumholz

HM, Mosca L., Pearson T., Pfeffer MA, Taubert KA AHA/ ACC guidelines for secondary prevention for patients with coronary and o ther atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Call Cardiol . 2006; 47:2130-9. doi : 10.1016/j. jacc.2006.04.026.

23. Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck -Brentano C., Prescott E., Storey RF, Deaton C., Cuisset T., Agewall S., Dickstein K., Edvardsen T., Escaned J.,

Gersh BJ, Svitil P., Gilard M., Hasdai D., Hatala R., Mahfoud F., Masip J., Muneretto C., Valgimigli M., Achenbach S., Bax JJ; ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41:407-77. doi: 10.1093/eurheartj/ehz425.

24. American Diabetes Association/ADA. Flu and pneumonia shots. 2020. Available at: https://www.diabetes . org/diabetes/medication-management/flu-and- neumonia - shots

(accessed May 6, 2020).

25. WHO (World Health Organization). Vaccine use. 2020. Available at: https://www.who.int/ influenza/vaccines/use/ en / (accessed June 27, 2020)

26. Drapkina O.M. , Shishkova V.N. , Burns S.A., Gorshkov A.Yu., Ryzhakova L.N., Vaccination against a new coronovirus infection in patients with a burdened cardiovascular and autoimmune history.// BAK . - 202